Eli Lilly and Company shares surged on May 30, 2026. The company released breakthrough clinical trial data for its next-generation obesity drug, Retatrutide.
Trial participants achieved weight-loss results comparable to bariatric surgery. These results exceeded the efficacy of currently available injectable GLP-1 therapies.
The announcement strengthens Lilly's dominance in the weight-loss market and intensifies pressure on competitors like Novo Nordisk. Analysts raised price targets as shares climbed on high trading volume.